Korro Bio (KRRO) investor relations material

Company overview and business model

• Focuses on developing RNA editing-based genetic medicines for rare and prevalent diseases, leveraging a proprietary OPERA platform for precise, transient RNA edits to address unmet medical needs.

• Utilizes oligonucleotide-based approaches with GalNAc-conjugated delivery for subcutaneous administration, aiming for increased specificity and improved tolerability.

• Lead program KRRO-121 targets hyperammonemia, including urea cycle disorders and hepatic encephalopathy, by editing GS mRNA to enhance ammonia clearance.

• Business model includes advancing a portfolio of differentiated RNA editing programs and leveraging established regulatory pathways for oligonucleotide medicines.

Financial performance and metrics

• Raised approximately $85 million in gross proceeds through a private placement of common stock and pre-funded warrants in March 2026.

• 4,501,928 shares sold at $11.11 per share and 3,148,836 pre-funded warrants at $11.109 per warrant.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; only nominal proceeds from warrant exercises ($0.001 per share).

• Covers registration expenses except for underwriting discounts, commissions, and transfer taxes, which are borne by selling stockholders.